
    
      All subjects will take SAR245409 twice daily. All subjects will receive SAR245409 as long as
      there is clinical benefit.

      Combination therapy with SAR245409, bendamustine and rituximab , will be administered over a
      28 day cycle for up to 6 to 8 cycles.

      Subjects receiving the doublet combination , SAR245409 plus rituximab will receive weekly
      rituximab for 4 - 8 weeks. Monthly Rituximab may be continued beyond 8 weeks.
    
  